At the First Moscow State Medical University named after. I.M. Sechenov started clinical trials of a drug from the ChemRar Group of Companies for the treatment of depression and panic disorder. The antidepressant and antianxiety effect is achieved due to the effect on adrenergic, dopamine, serotonin and histamine receptors, the company’s press service said.
It is noted that the drug does not cause drowsiness or withdrawal symptoms and has an antipathetic effect. Previously, it had already been approved in Russia for medical use in the treatment of generalized anxiety disorder and adaptation disorders, including in elderly patients.
For the production of the active pharmaceutical substance, Sechenov University and AFS-Technologies LLC (part of the ChemRar Group of Companies) received a government subsidy. “Over the past five years, we have created an advanced research base and developed competencies in drug development. The joint implementation of this project with the ChemRar group of companies serves as a good confirmation of its relevance in the industry,” the message quotes the words of the project leader, director of the Institute of Translational Medicine and Biotechnology of the First Moscow State Medical University, Vadim Tarasov.
